Evidence map›Paper›PMID 33166606›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2020

Tumor-mesoporous silica nanoparticle interactions following intraperitoneal delivery for targeting peritoneal metastasis.

Derek Hargrove, Brian Liang, Raana Kashfi-Sadabad, Gaurav N Joshi, Laura Gonzalez-Fajardo, Sterling Glass, Michael Jay, Andrew Salner, Xiuling Lu

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Derek HargroveDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, USA.
Brian LiangSchool of Medicine, University of Connecticut, Storrs, CT, USA.
Raana Kashfi-SadabadDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, USA.
Gaurav N JoshiDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, USA.
Laura Gonzalez-FajardoDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, USA.
Sterling GlassDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, USA.
Michael JayEshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Andrew SalnerHelen and Harrry Gray Cancer Center, Hartford Hospital Department of Radiation Oncology, Hartford, CT, USA.
Xiuling LuDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, USA. Electronic address: xiuling.lu@uconn.edu.
University of Connecticut · USHartford Hospital · USUniversity of North Carolina at Chapel Hill · US

Funding

Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer MetastasesR41CA239989 · NCI · NAMI THERAPEUTICS CORP. · PI LU, XIULING · 2019 to 2019
$225k
Intraperitoneal Delivery of Targeted Nanoparticles for Metastatic Ovarian CancerR03CA184394 · NCI · UNIVERSITY OF CONNECTICUT STORRS · PI LU, XIULING · 2015 to 2016
$158k
NCI NIH HHS R03 CA184394NCI NIH HHS R41 CA239989
6 · The paper itself

Abstract

The use of intraperitoneal administration of nanoparticles has been reported to facilitate higher concentrations of nanoparticles in metastatic peritoneal tumors. While this strategy is appealing for limiting systemic exposure of nanocarrier delivered toxic cargoes and increasing nanoparticle concentrations in avascular peritoneal tumors, little is known about the mechanism of nanoparticle accumulation on tumor tissues and currently, no nanoparticle-based product has been approved for intraperitoneal delivery. Here, we investigated the nanoparticle-specific characteristics that led to increased peritoneal tumor accumulation using MCM-41 type mesoporous silica nanoparticles as our model system. We also investigated the components of the peritoneal tumor stroma that facilitated nanoparticle-tumor interaction. The tumor extracellular matrix is the main factor driving these interactions, specifically the interaction of nanoparticles with collagen. Upon disruption of the collagen matrix, nanoparticle accumulation was reduced by 50%. It is also notable that the incorporation of targeting ligands did not increase overall tumor accumulation in vivo while it significantly increased nanoparticle accumulation in vitro. The use of other particle chemistries did not grossly affect the tumor targetability, but additional concerns arose when those tested particles exhibited significant systemic exposure. Mesoporous silica nanoparticles are advantageous for intraperitoneal administration for the treatment of peritoneal metastasis due to their physical stability, tumor targetability, strong interaction with the collagen matrix, and extended peritoneal residence time. Maximizing nanoparticle interaction with the tumor extracellular matrix is critical for developing strategies to deliver emerging therapeutics for peritoneal cancer treatment using nanocarriers.

Indexed as

NanoparticlesPeritoneal NeoplasmsCell Line, TumorDrug Delivery SystemsHumansInjections, IntraperitonealPorositySilicon DioxideSilicon DioxideNanoparticlePeritoneal metastasisSurface interactionTargetingTumor microenvironment

Identifiers

PMID33166606
PMCPMC7749032
OpenAlexW3096677453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.